

1 Recruitment, Consent and DNA Sample Acquisition in a 2 U.S. Precision Health Cohort During the COVID-19 Pandemic

3 Allyson M. Derry¹, Yvette Strong¹, Davia Schioppo¹, Joni Cotter¹, Geisa M. Wilkins¹, Laura I.
4 Siqueiros¹, Andrea Ouyang¹, Kathleen Hulseman¹, Joseph Petrosino¹, Lorrin Liang¹, Megan
5 Stevenson¹, Tiffany Elianne Aguilera¹, Alexandria L. Soto², Katherine Meurer², Alison L. Herman²,
6 Inessa Cohen², Guido J. Falcone², Erin E. Longbrake², Cassius I. Ochoa Char³, Kelly M.
7 Anastasio¹, Michael F. Murray⁴

8 ¹ Yale Center for Clinical Investigation, Yale School of Medicine, New Haven, CT, USA.

9 ² Department of Neurology, Yale School of Medicine, New Haven, CT, USA.

10 ³ Division of Vascular Surgery, Department of Surgery Yale School of Medicine, New Haven, CT, USA.

11 ⁴ Department of Genetics, Yale School of Medicine, New Haven, CT, USA.

12
13 **Correspondence to:** Prof. Michael F. Murray, Department of Genetics, Yale School of Medicine, 333 Cedar Street,
14 New Haven, CT, 06510, USA. E-mail: michael.murray@yale.edu; ORCID: 0000-0003-2872-9816

15 Received: date month year

16 [e.g., 1 Jan 2021]

17 Abstract

18
19 **Aim:** The Yale Generations Project (YGP) is a precision health cohort initiative that began enrollment in
20 New Haven Connecticut USA in July 2019. In March 2020, after nine months of operation, pandemic
21 restrictions prompted abrupt changes to staff availability as well as changes to the project's recruitment,
22 consenting, and sample acquisition. This manuscript describes the successful addition of remote
23 recruitment, consenting, and DNA sampling to YGP workflows during the initial 27-months of pandemic
24 restrictions ending June 30, 2022.

25 **Methods:** The initial YGP protocol established face-to-face workflow for recruiting, consenting and
26 peripheral blood collection. A telemedicine consent protocol was initiated in April of 2020, and a remote
27 saliva collection was established in October of 2020. De-identified data was extracted from YGP dataset
28 and reported here.

29 **Results:** At the completion of YGP's initial 36 months (9-months pre-pandemic and 27-months
30 pandemic) YGP enrolled N=4949 volunteers. There were N=1,950 (216.7 per month) volunteers
31 consented pre-pandemic and N=2,999 (111.1 per month) during pandemic. The peak consenting month
32 was February 2020 with N=428. DNA sample acquisition peaked in the pre-pandemic month of
33 February 2020 with N=291 peripheral blood draws, and in the pandemic period the peak DNA
34 acquisition month was November 2020 with N=176 (N=68 peripheral blood draws and N=108 saliva
35 samples).

36 **Conclusion:** The YGP successfully transitioned from pre-pandemic recruiting, consenting and sample
37 acquisition model that was exclusively face-to-face, to pandemic model that was predominantly remote.
38 The added value of remote recruiting, consenting, and sampling has led to plans for an optimized hybrid
39 model post-pandemic.

40 **Keywords:** genomics, precision health, COVID-19, cohort

41 INTRODUCTION

42
43 The healthcare infrastructure in the United States includes 637 distinct health systems [1]. In the last
44 twenty years, a small number of these health systems have established precision health cohorts in which
45 volunteers are recruited, consented, and provide a DNA sample for genomic sequencing, and are then
46 given genomic screening results that can be used for pharmacogenomic decision making and for
47 preventive care related to identified monogenic risk for predisposition to cancer and heart disease [2-5].

48 The Yale New Haven Health system (YNHH) together with the Yale School of Medicine established
49 such a program in July of 2019 in the state of Connecticut. This project was named the Yale Generations
50 Project (YGP) which had a formal launch ceremony in September of 2019^[6]. The YGP strategy included
51 a pre-launch phase from July 2019 until September 2019, followed by a recruitment ramp-up phase. The
52 recruitment ramp-up phase was expected to last an additional nine months, with the goal of reaching a
53 steady state of enrollment of greater than 800 volunteers per month by the end of year one (i.e., June
54 2020). The state of Connecticut, which borders New York in the northeastern region of the country, saw
55 the beginning of significant community spread of SARS-CO2 during March of 2020^[7]. By the end of
56 that month COVID-19 institutional precautions were undertaken, including suspension of outpatient
57 encounters related to non-therapeutic research at Yale. YGP has observed all institutional and
58 governmental infection control mandates during the COVID-19 pandemic period described in this
59 manuscript, and the effect of these mandates on protocols and growth of the cohort are described.

60 METHODS

61
62 The YGP plan was to launch the project in the second half of 2019 and to first establish and optimize
63 face-to-face recruitment, consenting and DNA sample collection. There was a plan to explore remote
64 options for recruitment, consenting and DNA collection once: [1] face-to-face workflows were fully
65 optimized, and [2] the project staffing plan of eleven “full-time equivalents” (FTEs) consenters was
66 realized.

67
68 During March of 2020, hiring was halted at nine full-time staff, who increasingly needed to be urgently
69 diverted to other projects and duties with rising local COVID-19 cases. In addition to staffing
70 interruptions in March 2020, there were increasing interruptions to recruitment, consenting, and DNA
71 sampling during that month, particularly in the second half of that month. The Project leadership
72 enabled a plan to initiate remote recruitment and consenting starting in April of 2020. A workflow for
73 remote DNA sample collection took longer to establish and was not fully approved, tested, and
74 operationalized until October of 2020. In **Table 1** below, there is a side-by-side description of the major
75 features of the pre-pandemic face-to-face workflow (July 2019 to March 2020) and the pandemic remote
76 workflows (April 2020 to June 2022). It is noted that the face-to-face workflows with appropriate
77 personal protective equipment continued at a low level during the pandemic where possible (e.g.,
78 hospitalized volunteers). The fluctuating month-to-month staffing levels are presented in
79 **Supplementary Table 1**.

80
81 The project staff were able to work from home for most aspects of their jobs during the pandemic period.
82 The exception to that was the need for at least one onsite staff member to process the saliva collection
83 kits that arrived by courier. The processing included accessioning the samples that arrived, and then
84 sending the samples to the hospital’s clinical laboratory for DNA isolation, sequencing, and genotyping.

85
86 All volunteers had a YNHH electronic health record (EHR), and this allowed for a de-identified
87 tabulation of data points of interest in **Table 2** including: sex, race, and ethnicity. In addition, whether
88 the volunteer was an established patient within the YNHH or if volunteering for the project prompted a
89 new registration to the health system, as well as whether the volunteer resided within the state of
90 Connecticut or outside of Connecticut, and whether the enrollment was face-to-face or remote.

91
92

MAJOR TASKS	DISCRETE STEPS	Pre-Pandemic Methods (Established June 2019-March 2020)	Pandemic Methods (Added April 2020-June 2022)
RECRUITMENT	Project Promotion	<p>Consenters setup recruitment tables in both health system and community sites.</p> <p>Consenters distributed project informational documents to interested individuals.</p> <p>Targeted recruitment and consenting within select clinical programs.</p>	<p>YGP leadership and YNHH physicians collaborated to identify groups of patients for outreach.</p> <p>Consenters contacted potential volunteers via electronic messages, phone calls, mailed letters.</p> <p>Public messaging about YGP via website and public announcements.</p>
	Case Identification	Interested volunteers present themselves to the recruiters.	<p>Potential participants responded to contact with expressed interest in project.</p> <p>Self-identified volunteers reached out independently to project.</p>
CONSENT	Individualized Informational Exchange	Face-to-face discussion between trained consentor and volunteer. Describing project, review consent document, and answer questions.	Teleconference discussion between trained consentor and volunteer. Describing project, review consent document, and answer questions.
	EHR Registration	Consentor creates an EHR in real time for any previously unregistered volunteers.	Consentor creates an EHR remotely for any previously unregistered volunteers.
	Informed Consent	Consentor has volunteer electronically sign consent document on the computer tablet.	Consentor documents volunteer's verbal consent to YGP during tele-video consent meeting.
DNA SAMPLE ACQUISITION	EHR Clinical Order Placement	Signed consent triggers a clinical order for blood draw for whole exome sequence and SNP array.	Verbal consent triggers a clinical order for saliva collection for whole exome sequence and SNP array.
	Volunteer Sample Collection Method	<p>Volunteer presents to any one of the health system's 500 phlebotomy stations for peripheral blood draw to fulfill clinical order in EHR.</p> <p>Volunteer opts for phlebotomy visit as either for project sample alone, or in conjunction with other clinical sample collection.</p>	<p>Saliva collection kit shipped to volunteer's home.</p> <p>Volunteer teleconferences with member of consent team for "coached" sample collection.</p> <p>Volunteer ships sample to YGP office.</p>

93

94 **TABLE 1. Elements of the YGP's Pre-Pandemic and Pandemic Workflows for Recruitment, Consent**
95 **and DNA Sample Acquisition.**

96

97 **RESULTS**

98

99 **Observed Differences in Pre-pandemic and Pandemic Demographics**

100

101 We observe several trends within the data displayed in **Table 2** below. There was an increase in the
 102 percentage of male volunteers and a decrease in the percentage of Hispanic volunteers during the
 103 pandemic. The percentage of African-American volunteers decreased and the percentage of those who
 104 did not provide race and ethnicity information increased amongst those joining the project remotely.
 105 There was an increased percentage of volunteers who were established YNHH patients as well as an
 106 increased percentage of volunteers who resided outside of the state of Connecticut during the pandemic
 107 period.
 108

	PRE-PANDEMIC (9 months)	PANDEMIC PERIOD (27 months)			TOTAL
	Face to Face	Face to Face	Remote	Combined	
Total	1950	247	2752	2999	4949
Sex					
Female	1416 (72.62%)	140 (56.68%)	1638 (59.52%)	1778 (59.29%)	3194 (64.54%)
Male	534 (27.38%)	107 (43.32%)	1114 (40.48%)	1221 (40.71%)	1755 (35.46%)
Race					
American Indian or Alaska Native	8 (0.41%)	0 (0.00%)	11 (0.40%)	11 (0.37%)	19 (0.38%)
Asian	72 (3.69%)	6 (2.43%)	102 (3.71%)	108 (3.60%)	180 (3.64%)
Black or African American	265 (13.59%)	39 (15.79%)	239 (8.68%)	278 (9.27%)	543 (10.97%)
Native Hawaiian or Other Pacific Islander	5 (0.29%)	0 (0.00%)	9 (0.33%)	9 (0.30%)	14 (0.28%)
White or Caucasian	1349 (69.18%)	171 (69.23%)	1943 (70.60%)	2114 (70.49%)	3463 (69.97%)
Not Provided	251 (12.87%)	31 (12.55%)	448 (16.28%)	479 (15.97%)	730 (14.75%)
Ethnicity					
Hispanic or Latino	223 (11.44%)	22 (8.91%)	261 (9.48%)	283 (9.44%)	506 (10.22%)
Non-Hispanic	1624 (83.28%)	213 (86.23%)	2201 (79.98%)	2414 (80.49%)	4038 (81.59%)
Not Provided	103 (5.28%)	12 (4.86%)	290 (10.54%)	302 (10.07%)	405 (8.18%)
YNHH EHR Established					
Prior to Volunteering	1833 (94.00%)	244 (98.79%)	2717 (98.73%)	2961 (98.73%)	4794 (96.87%)
In Conjunction with Volunteering	117 (6.00%)	3 (1.21%)	35 (1.27%)	38 (1.27%)	155 (3.13%)
Residence					
Inside Connecticut	1843 (94.51%)	221 (89.47%)	2406 (87.43%)	2627 (87.60%)	4470 (90.32%)
Outside Connecticut	107 (5.49%)	26 (10.53%)	346 (12.57%)	372 (12.40%)	479 (9.68%)

109

110 **TABLE 2. De-identified Demographic and Related Data from Electronic Health Record (EHR) of the**
 111 **YGP Volunteers over the period of this report.**


112

113


114 **Variation in Monthly Consenting and DNA Sample Collection During this Study**

115

116 The total number of volunteers who were consented during the 36 months recorded in this manuscript
 117 were 4,949. In the same period, the total number of DNA sample collections was 3,926. There is
 118 typically a lag in DNA collection following consenting in projects with this design, however a 20.67%
 119 gap appears to be exaggerated due to limitations associated with the pandemic ^[8].



120
121



122
123

124 **FIGURE 1A AND 1B. The month-to-month tallies for consenting (1A) and sample acquisition (1B).**

125

126 In **Figure 1A and B**, the month-to-month tallies for consenting and sample collection are presented.
127 This information is presented in tabular form in **Supplemental tables 2 and 3**. Both figures demonstrate
128 a drop-off in volunteer consents and samples starting in March 2020, coinciding with the initiation of
129 pandemic precautions and staff re-assignments in the second half of that month.

130

131 As of June 30th 2022 there were N=4949 volunteers enrolled in YGP. Of these, there were N=1,950
132 (216.7 per month) volunteers consented pre-pandemic, and N=2,999 (111.1 per month) volunteers during
133 pandemic. DNA sample acquisition peaked in the pre-pandemic month of February 2020 with N=291
134 peripheral blood draws, and in the pandemic period the peak DNA sample acquisition month was
135 November 2020 with N=176 (N=68 peripheral blood draws and N=108 saliva samples).

136

137

138 **DISCUSSION**

139

140 The project's trajectory at the end of 2019 and the beginning of 2020 was aligned with the initial project
141 goal of hiring a consent team of 11 FTE responsible for consenting greater than 800 volunteers per
142 month, however that goal was not achieved due to pandemic associated limitations in the period reported
143 here. Nevertheless, the YGP did recruit and consent nearly 3,000 volunteers during the 27 months of
144 COVID restrictions reported here, making it the most successful clinical research project recruitment at
145 Yale during the pandemic.

146

147 The observed differences in the volunteer demographics in the pre-pandemic and the pandemic phases
148 are believed to be multi-factorial, and they offer insights into ways to craft a post-pandemic strategy that
149 will allow the project to meet recruitment goals, including increased diversity and inclusion. The project
150 plan is to renew face-to-face recruitment and consenting as part of an effort to increase the number of
151 African American and Hispanic volunteers, while maintaining the remote consenting efforts that increase
152 the geographic reach of the project.

153

154 Currently in Connecticut, most of the pandemic related obstacles to YGP recruitment, consenting, and
155 DNA sample acquisition have been resolved. Like other groups around the world, the YGP leadership
156 plans to use the data obtained in the 36-month period described here to inform optimized hybrid
157 workflows for future work^[9].

158

159 **DECLARATIONS**

160 **Acknowledgments**

161 The authors of this manuscript would like to acknowledge Richard Hintz for his work with de-identified
162 database searches.

163 **Authors' contributions**

164 Contributed to the conception and design of the study: AM Derry, Y Strong, KM Anastasio MF Murray,

165 Contributions to the acquisition, analysis, or interpretation of data for the work: AM Derry, Y Strong, D
166 Schioppo, J Cotter, GM Wilkins, LI Siqueiros, A Ouyang, K Hulseman, J Petrosino, L Liang, M
167 Stevenson, TE Aguilera, AL Soto, K Meurer, AL Herman, I Cohen, GJ Falcone, EE Longbrake, CI
168 Ochoa Char, KM Anastasio, MF Murray

169 **Availability of data and materials**

170 Not applicable

171 **Financial support and sponsorship**

172 No external support or sponsorship

173 **Conflicts of interest**

174 All authors declared that there are no conflicts of interest

175 **Ethical approval and consent to participate**

176 The Yale Institutional Review Board (IRB) approved the protocol and the consent for Yale Generations
177 Project (study HIC#2000024015). All patients were consented via the IRB approved process.

178 **Consent for publication**

179 Not applicable

180 **Copyright**

181 © The Author(s) 2021.

182 REFERENCES

183

- 184 1. Furukawa MF, Kimmey L, Jones DJ, Machta RM, Guo J, Rich EC. Consolidation of Providers into
185 Health Systems Increased Substantially, 2016–18. *Health Affairs*. 2020;39:1321–5. [PMID:
186 32744941 DOI: 10.1377/hlthaff.2020.00017]
- 187 2. Schwartz MLB, McCormick CZ, Lazzeri AL, Lindbuchler DM, Hallquist MLG, Manickam K, et
188 al. A Model for Genome-First Care: Returning Secondary Genomic Findings to Participants and
189 Their Healthcare Providers in a Large Research Cohort. *The American Journal of Human Genetics*.
190 2018;103:328–37. [PMID: 30100086 DOI: 10.1016/j.ajhg.2018.07.009]
- 191 3. Christensen KD, Bell M, Zawatsky CLB, Galbraith LN, Green RC, Hutchinson AM, et al. Precision
192 Population Medicine in Primary Care: The Sanford Chip Experience. *Frontiers in Genetics*.
193 2021;12:626845. [PMID: 33777099 DOI: 10.3389/fgene.2021.626845]
- 194 4. Grzymalski JJ, Elhanan G, Morales Rosado JA, Smith E, Schlauch KA, Read R, et al. Population
195 genetic screening efficiently identifies carriers of autosomal dominant diseases. *Nature Medicine*.
196 2020;26(8):1235–9. [PMID: 32719484 DOI: 10.1038/s41591-020-0982-5]
- 197 5. Damrauer SM, Chaudhary K, Cho JH, Liang LW, Argulian E, Chan L, et al. Association of the
198 V122I Hereditary Transthyretin Amyloidosis Genetic Variant with Heart Failure Among
199 Individuals of African or Hispanic/Latino Ancestry. *JAMA*. 2019;322(22):2191. [PMID: 31821430
200 DOI: 10.1001/jama.2019.17935]
- 201 6. Forman R. Yale Launches Comprehensive DNA Sequencing Project, With Aim of Predicting,
202 Preventing, and Treating Gene-related Diseases. Available from: [https://medicine.yale.edu/news-](https://medicine.yale.edu/news-article/yale-launches-comprehensive-dna-sequencing-project-with-aim-of-predicting-preventing-and-treating-gene-related-diseases/)
203 [article/yale-launches-comprehensive-dna-sequencing-project-with-aim-of-predicting-preventing-](https://medicine.yale.edu/news-article/yale-launches-comprehensive-dna-sequencing-project-with-aim-of-predicting-preventing-and-treating-gene-related-diseases/)
204 [and-treating-gene-related-diseases/](https://medicine.yale.edu/news-article/yale-launches-comprehensive-dna-sequencing-project-with-aim-of-predicting-preventing-and-treating-gene-related-diseases/) [last accessed 17 Dec 2022]
- 205 7. Jiang J, Peterson E, Heimer R. COVID-19 Updated Data & Developments - 3.30.2020. Yale
206 School of Public Health. Available from: [https://ysph.yale.edu/news-article/covid-19-updated-data-](https://ysph.yale.edu/news-article/covid-19-updated-data-and-developments---3302020/)
207 [and-developments---3302020/](https://ysph.yale.edu/news-article/covid-19-updated-data-and-developments---3302020/) [Last accessed 17 Dec 2022]
- 208 8. Carey DJ, Fetterolf SN, Davis FD, Faucett WA, Kirchner HL, Mirshahi U, et al. The Geisinger
209 MyCode community health initiative: an electronic health record–linked biobank for precision
210 medicine research. *Genetics in Medicine*. 2016;18(9):906–13. [PMID: 26866580 DOI:
211 10.1038/gim.2015.187]
- 212 9. Loucks TL, Tyson C, Dorr D, et al. Clinical Research During the COVID-19 Pandemic: The Role
213 of Virtual Visits and Digital Approaches. *Journal of Clinical and Translational Science*. 2021;1–
214 28. [PMID: 34192057 DOI: 10.1017/cts.2021.19]